Philadephia, PA (PRWEB) January 21, 2014 -- The prescription drug safety advocates at DrugRisk.com have added new information to the site for patients and families of those who have taken the antipsychotic drug Risperdal. Court records show lawsuits alleging the drug caused abnormal breast growth have now spread to federal court*.
DrugRisk is a free resource center for consumers that use popular prescription drugs. By providing the latest recalls, safety alerts, research and litigation news, patients can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.
Risperdal is an antipsychotic medication approved by the FDA to treat schizophrenia, bipolar disorder and autism in adults and adolescents. However, Johnson & Johnson recently paid $2.2 billion in fines and pled guilty to federal criminal charges of promoting it for unapproved uses, such as treating ADHD in children**.
DrugRisk has added studies linking Risperdal to gynecomastia, or abnormal breast growth that can be accompanied by milk production***. A recent study also found antipsychotic drugs like Abilify, Risperdal, Seroquel and Zyprexa may triple the risk of type-2 diabetes in children****.
Parents have already filed lawsuits in a Pennsylvania state court alleging Risperdal caused abnormal breast growth in children, leading Johnson & Johnson to pay settlements*****.
Now, according to court documents obtained by DrugRisk, a lawsuit filed by a young man alleging he developed abnormal breasts after he began taking Risperdal at age 7 has been moved to a federal court in Illinois*.
Anyone affected by abnormal breast growth or diabetes after taking Risperdal is urged to visit DrugRisk.com or speak with a lawyer about their legal options. Due to the specialized nature of these cases, DrugRisk only recommends lawyers who have already handled Risperdal lawsuits.
Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Risperdal and other antipsychotic drugs, or to speak with a lawyer.
*Michael Johnson v. Ortho-McNeil-Janssen Pharmaceuticals, Inc., Johnson & Johnson Co., Excerpta Inc., Elsevier Science Publishing Co. and Elsevier, Inc., Case No. 1:2013cv05689, U.S. District Court for the Northern District of Illinois, Eastern Division
**Reuters, 11/4/13; reuters.com/article/2013/11/04/us-jnj-settlement-idUSBRE9A30MM20131104
***Cedars-Sinai Division of Endocrinology, Sept. 2012; ncbi.nlm.nih.gov/pubmed/22862307
****Vanderbilt University Medical Center, 8/22/13; news.vanderbilt.edu/2013/08/antipsychotic-drug-use-in-children-for-moodbehavior-disorders-increases-type-2-diabetes-risk/
*****Bloomberg, 9/10/12; bloomberg.com/news/2012-09-10/j-j-settles-risperdal-lawsuit-on-opening-day-of-trial.html; Banks v. Janssen Pharmaceuticals, Philadelphia Court of Common Pleas, January Term 2010, Case No. 00618
Chris Schroeder, DrugRisk, http://www.DrugRisk.com, +1 888-415-1859, [email protected]